Solid Biosciences (NASDAQ:SLDB – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.01, Zacks reports.
Solid Biosciences Stock Up 3.8%
NASDAQ:SLDB opened at $6.52 on Thursday. Solid Biosciences has a twelve month low of $3.79 and a twelve month high of $11.45. The firm has a market capitalization of $699.11 million, a price-to-earnings ratio of -3.41 and a beta of 2.65. The stock’s 50 day moving average price is $7.62 and its two-hundred day moving average price is $7.65.
Analyst Ratings Changes
A number of equities research analysts recently commented on SLDB shares. Loop Capital set a $25.00 price objective on Solid Biosciences in a report on Monday, September 14th. Truist Financial upped their price target on Solid Biosciences from $16.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, August 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Solid Biosciences in a research report on Thursday, October 15th. Royal Bank Of Canada began coverage on shares of Solid Biosciences in a research note on Wednesday, September 16th. They set an “outperform” rating and a $18.00 price objective on the stock. Finally, UBS Group began coverage on shares of Solid Biosciences in a report on Wednesday, October 14th. They set a “buy” rating and a $20.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Solid Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $20.00.
Get Our Latest Stock Analysis on Solid Biosciences
Solid Biosciences Company Profile
Solid Biosciences Inc (NASDAQ: SLDB) is a biotechnology company focused on developing gene therapies for neuromuscular and other serious genetic diseases. The company uses adeno-associated virus (AAV) delivery technologies and genetic medicine approaches to develop treatments intended to address the underlying causes of disease.
Its lead investigational program, SGT-003, is being developed as a gene therapy for Duchenne muscular dystrophy, a severe X-linked muscle-wasting disorder. Solid Biosciences also has additional preclinical and clinical programs targeting other neuromuscular conditions, including diseases associated with defects in muscle proteins.
Featured Articles
- Five stocks we like better than Solid Biosciences
- Datadog’s Post-Earnings Sell-Off: A Buying Opportunity in Plain Sight?
- How Much of Tesla’s Robotaxi Future Is Already Priced In?
- 3 AI Infrastructure Plays Beyond Chipmakers
- Keurig Dr Pepper’s Beverage Growth Raises a Tough Question About Its Coffee Split
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
